Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 7—July 2023
Research

Sensitivity to Neutralizing Antibodies and Resistance to Type I Interferons in SARS-CoV-2 R.1 Lineage Variants, Canada

Rajesh Abraham Jacob, Ali Zhang1, Hannah O. Ajoge1, Michael R. D'Agostino1, Kuganya Nirmalarajah, Altynay Shigayeva, Wael L. Demian, Sheridan J.C. Baker, Hooman Derakhshani, Laura Rossi, Jalees A. Nasir, Emily M. Panousis, Ahmed N. Draia, Christie Vermeiren, Jodi Gilchrist, Nicole Smieja, David Bulir, Marek Smieja, Michael G. Surette, Andrew G. McArthur, Allison J. McGeer, Samira Mubareka, Arinjay Banerjee, Matthew S. Miller, and Karen MossmanComments to Author 
Author affiliations: McMaster University, Hamilton, Ontario, Canada (R.A. Jacob, A. Zhang, H.O. Ajoge, M.R. D'Agostino, W.L. Demian, S.J.C. Baker, L. Rossi, J.A. Nasir, E.M. Panousis, A.N. Draia, D. Bulir, M. Smieja, M.G. Surette, A.G. McArthur, M.S. Miller, K. Mossman); Sunnybrook Research Institute, Toronto, Ontario, Canada (K. Nirmalarajah, S. Mubareka); University of Toronto, Toronto (A. Shigayeva, C. Vermeiren, A.J. McGeer, S. Mubareka, A. Banerjee); University of Manitoba, Winnipeg, Manitoba, Canada (H. Derakhshani); Research Institute of St. Joe’s Hamilton, Hamilton (J. Gilchrist, N. Smieja, D. Bulir); Vaccine and Infectious Disease Organization, Saskatoon, Saskatchewan, Canada (A. Banerjee); University of Saskatchewan, Saskatoon (A. Banerjee); University of Waterloo, Waterloo, Ontario, Canada (A. Banerjee); University of British Columbia, Vancouver, British Columbia, Canada (A. Banerjee)

Main Article

Table 1

Clinical summary of patients from study of sensitivity to neutralizing antibodies and resistance to type I interferons in SARS-CoV-2 R.1 lineage variants, Canada*

Characteristic Value
Total no. samples 39
No. samples, wave 1 26
No. samples, wave 3
 13
Median age, total (IQR) 58 (46–68)
Median age, wave 1 (IQR) 63 (55–71)
Median age, wave 3 (IQR)
 53 (33–56)
Sex, total
M 20
F
 19
Sex, wave 1
M 13
F
 13
Sex, wave 3
M 7
F
 6
Median no. days to sampling from first COVID-19 positive test (IQR) 42 (25–71)
Hospital admission
14 (36)
Median days from symptom onset to admission (IQR)
 6 (2–10)
Symptoms
Asymptomatic 1 (2)
Fever 17 (43)
Cough 19 (54)
Shortness of breath
 8 (20)
Comorbidities
Diabetes 9 (23)
Cardiac illnesses 4 (10)
Vascular illnesses 13 (33)
Pulmonary illnesses 3 (8)
Renal illnesses 2 (5)
Neuromuscular illnesses 0 (0)
Liver illnesses 0 (0)
Gastrointestinal illnesses 0 (0)
Cancer conditions 3 (7)
Rheumatologic illnesses 1 (2)
Mental health diagnosis 3 (7)
Immunocompromised
 0 (0)
ICU admission
 4 (10)
Intubation 2 (5)

*Values are no. (%) except as indicated. ICU, intensive care unit; IQR, interquartile range.

Main Article

1These authors contributed equally to this article.

Page created: May 08, 2023
Page updated: June 20, 2023
Page reviewed: June 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external